AMS BioteQ (6864-TW) Teams Up with Middle Eastern Partners to Introduce SIPSIP® Dressings to the Region!

On March 25, 2025, AMS BioteQ (6864-TW) announced the signing of a Memorandum of Understanding (MoU) with four healthcare and medical equipment distribution companies in the Middle East. This collaboration aims to introduce AMS BioteQ’s SIPSIP® series of wound care products to the Middle Eastern market, with sales expected to commence in the second half of 2025. The initiative is set to provide effective wound management solutions for chronic wound patients in the region while offering innovative care solutions to local medical institutions.

 

Rising Demand for Chronic Wound Dressings Drives Market Growth in the Middle East

 

The increasing prevalence of diabetes and an aging population in the Middle East have led to a growing demand for chronic wound treatment, making it a key factor in AMS BioteQ’s expansion into the region. According to market research, the Middle Eastern chronic wound dressing market was valued at approximately $750 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of over 7%. Countries such as the United Arab Emirates (UAE) and Saudi Arabia, with their advanced economies, are particularly in need of high-quality and innovative wound care products. Additionally, data from the International Diabetes Federation (IDF) indicates that the number of diabetes patients in the Middle East and North Africa exceeded 73 million in 2021 and is expected to rise to 136 million by 2045, further driving demand for chronic wound management products.

 

Moreover, the modernization of healthcare systems in the Middle East, coupled with government investments in the healthcare sector, has created a favorable environment for innovative medical products. For instance, Saudi Arabia’s Vision 2030 plan emphasizes increased investment in healthcare infrastructure and innovative technologies. Despite these advancements, there remains a gap in the market for effective solutions to chronic wound infections and healing, presenting a significant opportunity for AMS BioteQ’s SIPSIP® series.

 

SIPSIP Series: A Game-Changer in Wound Care

 

The SIPSIP® series of dressings by AMS BioteQ utilizes moist wound healing therapy, offering excellent absorbency and anti-adhesive properties to create an optimal healing environment. These products not only meet the demand for high-performance wound care solutions in the Middle East but also address the current supply gap, providing a new option for chronic wound patients in the region.

 

Strategic Partnerships to Drive Middle Eastern Market Expansion

 

AMS BioteQ has partnered with four leading companies from the UAE, Saudi Arabia, and Turkey, each with a strong foothold in healthcare, medical equipment distribution, and biomedical engineering. These partners bring extensive market expertise and resources to support the successful integration of SIPSIP® dressings into the Middle Eastern market.

 

Partner Profiles:

 

1.SkyPharma (UAE):

A leading distributor of healthcare products, including pharmaceuticals, medical devices, and health supplements. SkyPharma’s extensive network of medical institutions and professional team will help accelerate the market entry and brand recognition of SIPSIP® dressings.

 

2.Kayan Al-Seha Medical (Saudi Arabia):

A renowned healthcare company in Saudi Arabia with robust distribution channels and market experience. Kayan Al-Seha is committed to introducing high-quality medical products to meet growing market demands.

 

3.Daleluna Medical Establishment (Saudi Arabia):

A specialized medical equipment distributor with expertise in the sales and distribution of medical devices and consumables. Daleluna’s deep understanding of the medical equipment market and stable customer base will be instrumental in AMS BioteQ’s expansion in Saudi Arabia.

 

4.GEM Biomedical (Turkey):

A company focused on biomedical engineering and consulting services, including hospital management, equipment planning, and medical solutions. GEM Biomedical will leverage its expertise and resources to promote the practical application of SIPSIP dressings in Middle Eastern hospital systems.

 

Market Launch to Benefit Middle Eastern Wound Care

AMS BioteQ plans to officially introduce the SIPSIP® series to the Middle Eastern market in the second half of 2025. This collaboration marks a significant step in the company’s global expansion strategy. With the superior performance of SIPSIP dressings and the strong market presence of its four partners, AMS BioteQ is well-positioned to gain a competitive edge and enhance its brand influence in the region.

Mr. Tsai Yi-Ju, Chairman of AMS BioteQ, stated, “We are honored to partner with these four Middle Eastern companies to promote the application of SIPSIP® dressings in the region. We believe this collaboration will not only strengthen AMS BioteQ’s competitiveness in the global market but also improve the quality of care for chronic wound patients in the Middle East.” Moving forward, the company remains committed to innovation and quality, striving to develop more high-performance medical products while actively expanding its international presence to achieve sustainable growth.

As the demand for chronic wound and diabetes-related wound treatment continues to rise in the Middle East, coupled with increasing government support for medical innovation, AMS BioteQ’s entry into the market is timely. Through its partnerships with SkyPharma, Kayan Al-Seha Medical, Daleluna Medical Establishment, and GEM Biomedical, AMS BioteQ is poised to deliver more effective and innovative treatment options to chronic wound patients in the Middle East while solidifying its position in the global market.